US Equity Markets
Positive Clinical Trial Results Propel Altamira Therapeutics (CYTO) Stock
Altamira Therapeutics Ltd. (NASDAQ: CYTO) experienced a significant stock surge this morning, rising by 33.92% to $1.91 as of the latest update. This uptick follows the company’s announcement regarding the successful NASAR clinical trial results for its Bentrio nasal spray,
